Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 901–1,000 of 1,002
Genes and neurons: molecular insights to fear and anxiety
Stoppel, C. M., Albrecht, A., Pape, H., & Stork, O. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00229.x · Cited by 25
“2001) and cannabinoidergic mechanisms (via CB1 receptors; Marsicano et al. 2002; Kathuria et al. 2003) in fear memory extinction but also suggest that these may act synergistically (Diana et al.”
BackgroundScarpelli, R., Sasso, O., & Piomelli, D. (2015) · ChemMedChem · doi:10.1002/cmdc.201500395 · Cited by 21
Self-citationLipozyme 435-catalyzed synthesis of eicosapentaenoyl ethanolamide in a solvent-free system
Wang, X., Chen, Y., Ma, Y., Jin, Q., & Wang, X. (2015) · Journal of Molecular Catalysis B Enzymatic · doi:10.1016/j.molcatb.2015.09.016 · Cited by 21
Abohalaka, R., Bozkurt, T. E., Nemutlu, E., Onder, S. C., & Şahin-Erdemli, İ. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101920 · Cited by 21
The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys
Stewart, J. L., & McMahon, L. R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01388.x · Cited by 20
“Fatty acid amide hydrolase inhibitors, such as URB 597, block the enzyme primarily responsible for the metabolism of anandamide and increase brain anandamide levels in rodents (Kathuria et al., 2003; Fegley et al., 2005), marmosets (Johnston et al.”
BackgroundKono, M., Matsumoto, T., Imaeda, T., Kawamura, T., Fujimoto, S., Kosugi, Y., Odani, T., Shimizu, Y., Matsui, H., Shimojo, M., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.023 · Cited by 22
Eisenstein, S. A., Holmes, P. V., & Hohmann, A. G. (2009) · Synapse · doi:10.1002/syn.20679 · Cited by 22
“) which selectively increases anandamide accumulation in intact rats, without altering levels of 2-AG (Kathuria et al., 2003).”
InfluentialBedside to Bench: The element of surprise
Piomelli, D. (2008) · Nature Medicine · doi:10.1038/nm0708-720 · Cited by 20
Self-citationReynoso-Moreno, I., Chicca, A., Flores-Soto, M. E., Paredes, J. M. V., & Gertsch, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00180 · Cited by 21
Tian, X., Liu, T., Li, L., Shao, B., Yao, D., Feng, L., Cui, J., James, T. D., & Ma, X. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05826 · Cited by 21
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson, J. L., Bilbrey, J. A., Felix, J. S., Makriyannis, A., & McMahon, L. R. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173192 · Cited by 21
Rat and human fatty acid amide hydrolases: Overt similarities and hidden differences
Venere, A. D., Dainese, E., Fezza, F., Angelucci, C. B., Rosato, N., Cravatt, B. F., Finazzi‐Agrò, A., Mei, G., & Maccarrone, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.021 · Cited by 21
3‐Heterocycle‐Phenyl N‐Alkylcarbamates as FAAH Inhibitors: Design, Synthesis and 3D‐QSAR Studies
Käsnänen, H., Myllymäki, M. J., Minkkilä, A., Kataja, A. O., Saario, S. M., Nevalainen, T., Koskinen, A. M. P., & Poso, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900390 · Cited by 23
Millns, P. J., Chimenti, M., Ali, N., Ryland, E., de Lago, E., Fernández‐Ruíz, J., Chapman, V., & Kendall, D. A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05236.x · Cited by 20
“Herewe report that in the presence of the FAAH inhibitor URB597, which prevents the metabolism of endocannabinoids and does not bind to CB1 receptors (Kathuria et al., 2003), NADA-evoked responses of DRG neurons are attenuated, in a CB1 receptor-dependent manner.”
BackgroundViana, T. G., Hott, S. C., Resstel, L. B. M., de Aguiar, D. C., & Moreira, F. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3793-x · Cited by 19
“Compounds that inhibit anandamide hydrolysis (FAAH inhibitors) induce anxiolytic-like effects in rats (Kathuria et al. 2003) and mice (Patel and Hillard 2006; Moreira et al.”
BackgroundFatty Acid Amide Hydrolase: An Integrative Clinical Perspective
Santoso, A. D., & Ridder, D. J. M. K. D. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0237 · Cited by 20
“23 A considerable amount of research has been conducted to advance FAAH modulation further into clinical application, resulting in more than 2500 articles from a database query in Web of Science, using the keywords ‘‘fatty acid amide hydrolase’’ or ‘‘FAAH.’’”
Fotio, Y., Tagne, A. M., Jung, K., & Piomelli, D. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06358-y · Cited by 19
“Preclinical and clinical studies have shed light into the role endocannabinoids play both in stress-coping processes and in the susceptibility to develop trauma-related psychopathologies (Hill et al. 2010b; Kathuria et al. 2003; Mayo et al. 2022; Patel and Hillard 2008; Stopponi et al. 2018).”
Self-citationJia, W., He, X., Jin, W., Gu, J., Yu, S., He, J., Yi, Z., Cai, B., Gao, H., & Yang, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116747 · Cited by 19
Munguba, H., Cabral, A. E. A., Leão, A. H. F. F., Barbosa, F. F., Izídio, G. S., Ribeiro, A. M., & Silva, R. H. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.03.006 · Cited by 22
Zhou, Y., & Kreek, M. J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.245621 · Cited by 19
“Pharmacologic and genetic manipulations (knockout or knock-in) of FAAH are found to alter anxiety-like and depression-like behaviors (Kathuria et al., 2003; Bortolato et al., 2007; Moreira et al., 2008; Gunduz-Cinar et al., 2013; Carnevali et al., 2015).”
BackgroundOpioid and Endocannabinoid System in Orofacial Pain
Zubrzycki, M., Stasiołek, M., & Zubrzycka, M. (2019) · Physiological Research · doi:10.33549/physiolres.934159 · Cited by 23
Inhibition of FAAH, TRPV1, and COX2 by NSAID–serotonin conjugates
Rose, T. M., Reilly, C. A., Deering‐Rice, C. E., Brewster, C., & Brewster, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.064 · Cited by 20
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH)
Tabrizi, M. A., Baraldi, P. G., Ruggiero, E., Saponaro, G., Baraldi, S., Romagnoli, R., Martinelli, A., & Tuccinardi, T. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.064 · Cited by 21
Carnevali, L., Rivara, S., Nalivaiko, E., Thayer, J. F., Vacondio, F., Mor, M., & Sgoifo, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.013 · Cited by 20
Self-citationSimonnet, A., Zamberletti, E., Cador, M., Rubino, T., & Caillé, S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.007 · Cited by 19
“Finally, inhibition of FAAH is well-known to block the degradation of AEA, however, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are also hydrolyzed by this enzyme (Kathuria et al., 2003).”
Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks
Viana, T. G., Bastos, J. D. R., Briânis, R. C., Hott, S. C., Machado, F. S. M., Coimbra, C. C., Resstel, L. B. M., de Aguiar, D. C., & Moreira, F. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.01.022 · Cited by 20
Bartoll, A., Toledano‐Zaragoza, A., Casas, J., Guzmán, M., Schuchman, E. H., & Ledesma, M. D. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911776 · Cited by 19
“Specifically, inhibition of the eCB-degrading enzyme FAAH has been successfully tested in animal models for inflammation, chronic pain, and anxiety, without remarkable adverse effects (Kathuria et al , 2003; Russo et al , 2007; Ahn et al , 2009).”
BackgroundTargeting Endocannabinoid System in Epilepsy: For Good or for Bad
Martínez-Aguirre, C., Çınar, R., & Rocha, L. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.12.013 · Cited by 20
Fatty Acid Amide Hydrolase (FAAH) Inhibition Plays a Key Role in Counteracting Acute Lung Injury
Genovese, T., Duranti, A., D’Amico, R., Fusco, R., Impellizzeri, D., Peritore, A. F., Crupi, R., Gugliandolo, E., Cuzzocrea, S., Paola, R. D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052781 · Cited by 18
Self-citationRodrigues, B. M. D. P., & Coimbra, N. C. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221115755 · Cited by 20
“, 2007; Patel and Hillard, 2006), elevated zero-maze model (Kathuria et al., 2003) and the place preference paradigm (Rutkowska et al.”
BackgroundNahvi, R. J., Tanelian, A., Nwokafor, C., Godino, A., Parise, E. M., Estill, M. S., Shen, L., Nestler, E. J., & Sabban, E. L. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114162 · Cited by 20
Mammalian Fatty Acid Amides of the Brain and CNS
Waluk, D. P., Battistini, M. R., Dempsey, D. R., Farrell, E. K., Jeffries, K. A., Mitchell, P. R., Hernandez, L. W., McBride, J. C., Merkler, D. J., & Hunt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00009-0 · Cited by 24
Chapter 16 Endocannabinoid System and Fear Conditioning
Resstel, L. B. M., Moreira, F. A., & Guimarães, F. S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(09)81016-9 · Cited by 21
de Fonseca, F. R., & Schneider, M. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00116.x · Cited by 18
“2003 Anandamide degradation and anxiety Kathuria et al. (2003) 2005 First clinical indication for cannabinoid CB1 receptor antagonists Van Gaal et al. (2005)”
BackgroundBarricklow, J., & Blatnik, M. (2013) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.05.003 · Cited by 18
Rademacher, D. J., Sullivan, E. M., & Figge, D. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1748-4 · Cited by 18
“2002) and the inhibition of the catabolism of the eCB, anandamide, produces an anxiolytic effect (Kathuria et al. 2003).”
The endocannabinoid gene faah2a modulates stress-associated behavior in zebrafish
Krug, R. G., Lee, H. B., Khoury, L. Y. E., Sigafoos, A. N., Petersen, M. O., & Clark, K. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190897 · Cited by 22
Vimalanathan, A., Gidyk, D. C., Diwan, M., Gouveia, F. V., Lipsman, N., Giacobbe, P., Nóbrega, J. N., & Hamani, C. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107965 · Cited by 21
“Doses of URB597, AM251 and WIN,55212–2 were selected based on efficacy shown by others (Haller et al., 2004; Kathuria et al., 2003).”
BackgroundAssociation of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder
Peiró, A. M., García‐Gutiérrez, M. S., Planelles, B., Femenía, T., Mingote, C., Jiménez-Treviño, L., Martínez-Barrondo, S., García‐Portilla, M. P., Sáiz, P. A., Bobes, J., et al. (2020) · Anxiety Stress & Coping · doi:10.1080/10615806.2020.1732358 · Cited by 18
A second N-acylethanolamine hydrolase in mammalian tissues
Ueda, N., Tsuboi, K., & Lambert, D. M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.017 · Cited by 18
“Furthermore, the administration of a potent FAAH inhibitor URB597 to mice enhanced the brain level of anandamide, and exhibited anti-nociceptive and anxiolytic effects (Kathuria et al., 2003).”
Anxiety Modulation by Cannabinoids—The Role of Stress Responses and Coping
Haller, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115777 · Cited by 20
“The first enzyme inhibitor developed was URB-597, which inhibits the enzyme FAAH [97].”
BackgroundNAPE-PLD in the ventral tegmental area regulates reward events, feeding and energy homeostasis
Castel, J., Li, G., Onimus, O., Leishman, E., Cani, P. D., Bradshaw, H. B., Mackie, K., Everard, A., Luquet, S. H., & Gangarossa, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02427-6 · Cited by 19
Madrid-Gambín, F., Gomez‐Gómez, À., Busquets-García, A., Haro, N., Marco, S., Mason, N. L., Reckweg, J. T., Mallaroni, P., Kloft, L., van Oorsouw, K. I. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112845 · Cited by 18
“For example, increased anandamide levels have been linked to antidepressant effects [8] or anxiolysis [32].”
BackgroundKondev, V., Morgan, A., Najeed, M., Winters, N. D., Kingsley, P. J., Marnett, L. J., & Patel, S. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.05.012 · Cited by 18
A rapid punishment procedure for detection of anxiolytic compounds in mice
Witkin, J. M., Morrow, D., & Li, X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1618-4 · Cited by 17
“…in the literature that are generally used in this species that include the elevated plus maze and a host of other ethologically based methods (e.g. Dawson and Tricklebank 1995; Fish et al. 2000; Van Gaalen and Steckler 2000; Griebel et al. 2001; Bilkei-Gorzo et al. 2002; Kathuria et al. 2003).”
BackgroundMethodCiuffreda, P., Xynomilakis, O., Casati, S., & Ottria, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147693 · Cited by 19
“…also leads to very high endogenous levels of fatty acid amides in the nervous system [68] and peripheral tissues [69], resulting in analgesic [68], anxiolytic [68], and anti-inflammatory [69] effects without showing the undesirable side effects linked to direct cannabinoid receptor agonists…”
BackgroundInfluentialMaples‐Keller, J. L., Watkins, L. E., Hellman, N. M., Phillips, N. L., & ROTHBAUM, B. O. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.010 · Cited by 20
The endocannabinoid system in the brain undergoes long-lasting changes following neuropathic pain
Zhang, M., Wang, T., Meng, F., Jiang, M., Wu, S., & Xu, H. (2024) · iScience · doi:10.1016/j.isci.2024.111409 · Cited by 20
“70 In conclusion, the positive feedback loop in which AEA increases CB1Rs expression in the IC provides an endogenous analgesic strategy for addressing neuropathic pain.”
Papahatjis, D. P., Nahmias, V. R., Nikas, S. P., Schimpgen, M., & Makriyannis, A. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200902880 · Cited by 20
Tian, G., Paschetto, K. A., Gharahdaghi, F., Gordon, E., Wilkins, D. E., Luo, X., & Scott, C. W. (2011) · Biochemistry · doi:10.1021/bi200552p · Cited by 19
Kiso, T., Watabiki, T., & Sekizawa, T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173194 · Cited by 16
Involvement of acid ceramidase in the degradation of bioactive N-acylethanolamines
Tsuboi, K., Tai, T., Yamashita, R., Ali, H., Watanabe, T., Uyama, T., Okamoto, Y., Kitakaze, K., Takenouchi, Y., Go, S., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158972 · Cited by 17
Greco, R., Demartini, C., Zanaboni, A. M., Francavilla, M., Reggiani, A. M., Realini, N., Scarpelli, R., Piomelli, D., & Tassorelli, C. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01449-1 · Cited by 17
“Most of these effects can be attributed to enhanced activation of the cannabinoid-1 (CB1) and CB2 receptors by non-metabolized AEA [9, 11, 15, 16], though a contribution of OEA/PEAdependent activation of PPAR-α was also described [17, 18].”
BackgroundSelf-citationBuwembo, A., Long, H., & Walker, C. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.057 · Cited by 19
No more pain upon G q‐protein‐coupled receptor activation: role of endocannabinoids
Hu, S. S., Ho, Y., & Chiou, L. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12475 · Cited by 21
RetractedAguilar, D. D., Giuffrida, A., & Lodge, D. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115612239 · Cited by 20
“We do not believe this to be due to the dose selected, as 0.3 mg/kg has been reported to maximally inhibit FAAH enzyme activity in vivo up to 6 hours following its administration, significantly elevate brain AEA, and induce CB1-dependent behavioral effects in rats (Kathuria et al., 2003).”
BackgroundInfluentialInteraction Between the Cannabinoid and Vanilloid Systems on Anxiety in Male Rats
Faraji, N., Komaki, A., & Salehi, I. (2017) · Basic and Clinical Neuroscience Journal · doi:10.18869/nirp.bcn.8.2.129 · Cited by 16
Endocannabinoid interactions in the regulation of acquisition of contextual conditioned fear
Balogh, Z., Szente, L., Bíró, L., Varga, Z. K., Haller, J., & Aliczki, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.11.007 · Cited by 18
“, 2005) and AEA levels (Cravatt et al., 2001; Cravatt et al., 1996; Kathuria et al., 2003; McKinney and Cravatt, 2005), and while the blockade of both FAAH and MAGL alters the levels of substrates of these enzymes besides AEA or 2-AG, none of these compounds were shown to exert significant,”
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis
Bortolato, M., Bini, V., & Tambaro, S. (2010) · Pharmaceuticals · doi:10.3390/ph3092799 · Cited by 17
“[141]), blockade of anandamide reuptake and degradation elicits anxiolytic and antidepressant-like effects [55,102,104,105,142], suggesting a key role of this endocannabinoid in emotional regulation.”
BackgroundMcFarland, M. J., Terebova, E. A., & Barker, E. L. (2006) · The AAPS Journal · doi:10.1208/aapsj080111 · Cited by 16
Uzuneser, T. C., Szkudlarek, H. J., Jones, M., Nashed, M. G., Clement, T., Wang, H., Ojima, I., Rushlow, W. J., & Laviolette, S. R. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac220 · Cited by 16
Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs
Zhao, H., Liu, Y., Cai, N., Liao, X., Tang, L., & Wang, Y. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s462785 · Cited by 17
“168 The above studies illustrate that the use of FAAH inhibitors enhances brain neurogenesis as well as interneuronal transmission. mTOR and neuropeptide Y (NPY) signaling may be associated with enhanced neurogenesis and neuroplasticity by FAAH inhibitors. mTOR signaling is essential for…”
BackgroundMakwana, R., Molleman, A., & Parsons, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00717.x · Cited by 17
“Similarly, application of all three FAAH inhibitors by themselves, up to concentrations that completely inactivate FAAH and lack affinity for the CB1 receptor in vitro (Deutsch et al., 1997; Bisogno et al., 1998; Kathuria et al., 2003), were also without effect on the EFSevoked contractions.”
BackgroundCeci, C., Onori, M. P., Macrì, S., & Laviola, G. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9510-z · Cited by 16
Batista, L. A., Bastos, J. D. R., & Moreira, F. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114566259 · Cited by 15
“Accordingly, selective FAAH inhibitors, such as URB597, promoted anxiolytic effects and knock-out mice lacking this enzyme showed reduced anxiety-like behaviours in the elevated plus maze (EPM) and the zero maze (Kathuria et al., 2003; Moreira et al., 2008; Patel and Hillard, 2006).”
BackgroundCeci, C., Mela, V., Macrì, S., Marco, E. M., Viveros, M., & Laviola, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3367-3 · Cited by 16
Design, synthesis and biological evaluation of potent FAAH inhibitors
Tuo, W., Leleu‐Chavain, N., Barczyk, A., Renault, N., Lemaire, L., Chavatte, P., & Millet, R. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.004 · Cited by 15
Iglesias, L. P., Fernandes, H. D. B., de Miranda, A. S., Pérez, M. M., Faccioli, L. H., Sorgi, C. A., Bertoglio, L. J., de Aguiar, D. C., Wotjak, C. T., & Moreira, F. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109314 · Cited by 17
Hama, A. T., Germano, P., Varghese, M. S., Cravatt, B. F., Milne, G. T., Pearson, J. P., & Sagen, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096396 · Cited by 15
Arylboronic acids as dual-action FAAH and TRPV1 ligands
Morera, E., Marzo, V. D., Monti, L., Allarà, M., Moriello, A. S., Nalli, M., Ortar, G., & PETROCELLIS, L. D. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.071 · Cited by 15
Pathak, S., Kumar, K. R., Kanta, H., Carr-Johnson, F., Han, J., Bashmakov, A., Faure, L., Ding, H., Vanarsa, K., Khan, S., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500291 · Cited by 15
“URB597 (cyclohexylcarbamic acid 39-carbamoylbiphenyl-3-yl ester) is a widely used, potent, and selective inhibitor of FAAH (28).”
BackgroundFreels, T. G., Lester, D. B., & Cook, M. N. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.01.010 · Cited by 16
Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors
Deplano, A., Cipriano, M., Moraca, F., Novellino, E., Catalanotti, B., Fowler, C. J., & Onnis, V. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1532418 · Cited by 15
“N-(4-(tert-Butyl)benzyl)-2–(4-isobutylphenyl)propanamide (6)”
Vozella, V., Ahmed, F., Choobchian, P., Merrill, C. B., Zibardi, C., Tarzia, G., Mor, M., Duranti, A., Tontini, A., Rivara, S., et al. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13166 · Cited by 15
“The relatively short half-life time of URB937 does not negatively impact the pharmacological potency and efficacy of the compound which, like other O-aryl carbamates, inhibits FAAH via covalent attack of the enzyme’s catalytic nucleophile.([27,28]) We used the new LC/MS-MS method, combined with measurements of FAAH ac…”
MethodSelf-citationGardiner, S., March, J., Kemp, P. A., & Bennett, T. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00363.x · Cited by 15
“Therefore, the first aim of the present study was to evaluate the effects of FAAH inhibition with URB597 (Kathuria et al., 2003; Piomelli et al., 2006) and/or COX-2 inhibition with parecoxib (Talley et al.”
BackgroundColombano, G., Albani, C., Ottonello, G., Ribeiro, A., Scarpelli, R., Tarozzo, G., Daglian, J. M., Jung, K., Piomelli, D., & Bandiera, T. (2014) · ChemMedChem · doi:10.1002/cmdc.201402374 · Cited by 18
Self-citationMcCallum, A. L., Limebeer, C. L., & Parker, L. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.010 · Cited by 15
“Furthermore, at the dose of 0.3 mg/kg, URB597 produces maximal efficacy in anyxiolytic-like (Kathuria et al., 2003; Patel and Hillard, 2006; Scherma et al., 2008a), anti-depressantlike (Gobbi et al., 2005) and anti-nausea-like effects (Cross-Mellor et al., 2007; Rock et al., 2008) in rats.”
BackgroundInfluentialURB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats
Hasanein, P., Parviz, M., Keshavarz, M., & Roohbakhsh, A. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-026 · Cited by 14
Inactivation of Anandamide Signaling: A Continuing Debate
Khairy, H. A., & Houssen, W. E. (2010) · Pharmaceuticals · doi:10.3390/ph3113355 · Cited by 15
“In preclinical studies, URB597 was found to produce analgesic, anxiolytic-like and antidepressant-like effects in rodents, which are not accompanied by overt signs of abuse liability.”
BackgroundCarnevali, L., Barbetti, M., Fotio, Y., Ferlenghi, F., Vacondio, F., Mor, M., Piomelli, D., & Sgoifo, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06473-w · Cited by 15
“Relatedly, preclinical studies have shown that globally active FAAH inhibitors such as URB597 (Kathuria et al. 2003) increase availability of endogenous FAEs and promote behavioral resilience to stress through mechanisms that have generally been ascribed to central processes, including enhanced…”
InfluentialSelf-citationO'Brien, L. D., Limebeer, C. L., Rock, E. M., Bottegoni, G., Piomelli, D., & Parker, L. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12360 · Cited by 15
“The catalytic activity of the FAAH enzyme has been found to impact other N-acylethanolamides as well as anandamide; such as oleoylethanolamide and palmitoylethanolamide (Bracey et al., 2002; Kathuria et al., 2003), bioactive molecules that act on non-cannabinoid receptors.”
BackgroundSelf-citationAhmed, M., Best, L. M., Pereira, C. F., Boileau, I., & Kloiber, S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104680 · Cited by 16
Jarzimski, C., Karst, M., Zoerner, A. A., Rakers, C., May, M., Suchy, M. T., Tsikas, D., Krauss, J. K., Scheinichen, D., Jordan, J., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04175.x · Cited by 14
Zahov, S., Drews, A., Hess, M., Elfringhoff, A. S., & Lehr, M. (2011) · ChemMedChem · doi:10.1002/cmdc.201000473 · Cited by 14
Belluomo, I., Matias, I., Pernègre, C., Marsicano, G., & Chaouloff, F. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13044 · Cited by 15
“This differential impact of JZL195 on AEA, PEA, and OEA was not due to the use of the latter inhibitor as the selective impairment of rat brain FAAH activity by another inhibitor, namely, URB597, leads to a higher accumulation in PEA and OEA than in AEA (Kathuria et al. 2003; Patel et al. 2005).”
BackgroundShang, Y., Wang, M., Hao, Q., Meng, T., Li, L., Shi, J., Yang, G., Zhang, Z., Yang, K., & Wang, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106031 · Cited by 14
Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase
Shoup, T. M., Bonab, A. A., Wilson, A. A., & Vasdev, N. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0789-1 · Cited by 14
“Pretreatment with the potent and selective FAAH inhibitor URB597 showed 995 % blockade in all regions.”
BackgroundInfluentialCisneros, J. A., Vandevoorde, S., Ortega‐Gutiérrez, S., Paris, C., Fowler, C. J., & López-Rodríguez, M. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070642y · Cited by 17
Closing the Gate to the Active Site
Mei, G., Venere, A. D., Gasperi, V., Nicolai, E., Masuda, K. R., Finazzi‐Agrò, A., Cravatt, B. F., & Maccarrone, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605653200 · Cited by 14
Hasanein, P., Shahidi, ., Komaki, A., & Mirazi, N. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.061 · Cited by 16
“URB597 has been shown to exert a moderate antinociceptive action in the mouse hot-plate test at a dose of 0.5 mg/kg (Kathuria et al., 2003).”
InfluentialHill, M. N. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.01.038 · Cited by 17
RETRACTED: Anandamide mediates cognitive judgement bias in rats
Kregiel, J., Małek, N., Popik, P., Starowicz, K., & Ryguła, R. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.009 · Cited by 13
RetractedWolfson, M. L., Aisemberg, J., Salazar, A. I., Rubio, A. P. D., Vercelli, C. A., & Franchi, A. M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.020 · Cited by 13
“In fact, in women undergoing in vitro fertilization and embryo transfer, high plasma AEA levels and low lymphocyte FAAH levels at 6 weeks after embryo transfer were associated with failure to achieve an ongoing pregnancy (Maccarrone et al., 2002).”
InfluentialDanan, D., Todder, D., Zohar, J., & Cohen, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126416 · Cited by 14
Almada, R. C., Falconi‐Sobrinho, L. L., da Silva, J. A., Wotjak, C. T., & Coimbra, N. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06127-3 · Cited by 14
“URB597 is one of the most well-characterised FAAH inhibitors among the several compounds synthesised and tested, which enhance endogenous anandamide signalling without directly interacting with cannabinoid receptors (Kathuria et al. 2003; Fegley et al. 2005; Piomelli et al. 2006).”
BackgroundDuranti, A., Beldarrain, G., Alvarez, A. A., Sbriscia, M., Carloni, S., Balduini, W., & Alconada, D. A. (2022) · Biomedicines · doi:10.3390/biomedicines11010028 · Cited by 15
“For example, it has been reported that FAAH knockdown mice show increased levels of AEA in the brain and other tissues leading to CB1 receptor-mediated analgesia [93,94], or a reduction in anxiety symptoms without the appearance of catalepsy [95].”
BackgroundSelf-citationThe anxiolytic effects of cannabinoids: A comprehensive review
Mallick, K., Khan, M. F., & Banerjee, S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173828 · Cited by 11
Fowler, C. J., & Tiger, G. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.01.016 · Cited by 13
Saario, S. M., McKinney, M. K., Speers, A. E., Wang, C., & Cravatt, B. F. (2011) · Chemical Science · doi:10.1039/c1sc00336d · Cited by 13
Saber-Tehrani, A. S., Naderi, N., Najarkolaei, A. H., Haghparast, A., & Motamedi, F. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0030-9 · Cited by 13
“URB597 is a FAAH inhibitor [7] that significantly increases the levels of anandamide, thereby potentiating the effects of anandamide at synapses [8].”
Background
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.